Ligand id: 9868

Name: lofexidine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 33.62
Molecular weight 258.03
XLogP 3.14
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In the UK lofexidine is administered to relieve symptoms in patients undergoing opioid detoxification. It is the first non-opioid to be used for managing opioid withdrawal symptoms. The US FDA approved its use in May 2018. Its use is not yet approved by the EMA (May 2018).
Mechanism Of Action and Pharmacodynamic Effects
Lofexidine mitigates the acute and painful symptoms of opioid withdrawal by suppressing the norepinephrine surge that produces the symptoms. α2-adrenoceptor agonism reduces norepinephrine release.
External links